**INVESTING IN WOMEN’S HEALTH**

AfCFTA - anchored Pharma Initiative: a Game Changer

This AfCFTA-anchored Pharmaceutical Initiative (Pharma Initiative) is an inclusive health and economic framework. It contributes to improved and economically sustainable access to safe medicines and the realization of the Pharmaceuticals Manufacturing Plan for Africa (PMPA) and Agenda 2063. The Pharma Initiative proposes localized production, pooled procurement and a harmonized regulatory and quality framework. Participating countries include the Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Mauritius, Rwanda, Seychelles, and the Sudan anchored on IGAD.

Maternal and child health burdens remain relatively high in Africa, (West Africa ranking the lowest), and with access to reproductive health products a key consideration. The intended macro improvements are complemented by social gains with significant job creation, a healthy future generation and increases in women's productivity.

Linking this health initiative to AfCFTA and AMA represents great opportunities to change and save lives, reduce poverty and contribute to inclusive and sustainable economic development of Africa. AfCFTA as a game changer is a critical component in the development of a scalable, reproductive Pharmaceutical Framework of Action. On the other hand, AMA guarantees continental public health, safety and security.

---

**AfCFTA** - Africa Continental Free Trade Area

**PMPA** - Pharmaceuticals Manufacturing Plan for Africa

**AMA** - African Medicines Agency
Justification for West Africa AfCFTA - anchored Pharma Initiative Launch
(maternal mortality ratio / 100,000 live birth, 2017)

The maternal mortality ratio varies across the 15 West African countries and also varies across income groups contributing to inequities to access, availability and affordability of maternal and reproductive health commodities.

Household spending on health

Out of pocket spending in the 15 West Africa countries on average 47%, higher than the African average of 36%.

Unsustainable Rising Government Costs/Debts

97% and 99% of trade budget spent on Pharmaceuticals and Vaccines imports respectively

AfCFTA and AMA are business blueprints for improving women and children's healthcare during and post COVID

Key findings from the Parent AfCFTA - anchored Pharma Initiative

Pooled Procurement

- 43% savings on a budget of $1.3 billion for maternal and child health products in the 10 participating countries through pooled procurement
- 7% on average improvement in availability, access and affordability through a centralized pooled procurement mechanism
- 60% cost savings achieved through the Ethiopian Pharmaceutical Pooled Procurement Supply Agency.

Local Production

- 5–15% efficiency gains through health delivery system in the 10 participating countries
- 21–76% improved accessibility of family planning products
- 10% increase in local production
- 5% improvement in doing business indicator

Harmonized Regulatory, Standards and Quality Framework

- 15% improvement on health outcomes through the engagement of private sector
- 15% efficiency gains in health care provision through digitization and data management
- ISO 9001:2000 Certification fulfills AMA requirement for Pharmaceutical Production

Results motivated by the AfCFTA - anchored Pharma Initiative

- Implementation of Centralized Pooled Procurement Mechanism in Pilot Countries
- Capacity building support provided to 1 Manufacturer selected through the Expression of Interest (EOI) process,
- Establishment and operationalization of AMSP leveraging on the 3 pillars of the Pharma Initiative
- Contributing to the acquisition of COVID-19 vaccines for African member States by providing technical backstopping to the establishment and operationalization of AVAT
- Roll - Out of the Pharma Initiative in West Africa in partnership with ABCHealth representing Private Sector and relevant Stakeholders

Data Source: WHO